Friday, November 7: Shares of Sakar Healthcare Ltd gained 2.54% to Rs 400 in Friday’s session after the company announced that it has received nine new Marketing Authorisations (MAs) for its oncology portfolio across the European Union (EU) and several emerging markets, bringing the total number of approved oncology products to 11.
According to the company, five oncology product dossiers — Carboplatin, Docetaxel, Irinotecan liquid injections, Gemcitabine lyophilised injection, and Tamoxifen tablets — have received regulatory approvals from Bulgaria within the EU. Additionally, Docetaxel injection has also been approved in Bosnia, further strengthening the company’s presence in Europe.
In emerging markets, approvals were received for Gemcitabine lyophilised injection, Abiraterone, Imatinib, and Capecitabine tablets in South East Asia, and Carboplatin injection in Latin America. All these dossiers were developed in-house at Sakar’s API-integrated, EU-GMP approved oncology formulation manufacturing facility, highlighting its expertise in high-quality drug development.
These new approvals pave the way for commercial exports of anti-cancer formulations to Europe, Latin America, and South East Asian countries. The company’s oncology range covers treatment for several major cancers, including gastrointestinal, colon, rectal, pancreatic, prostate, bladder, breast, ovarian, lung, blood, and bone marrow cancers.
Sakar Healthcare stated that the new authorisations mark a significant milestone in its strategy to expand its global oncology footprint, adding that more marketing approvals are expected in the coming months as additional dossiers remain under review across global markets.
Disclaimer:
The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
